"Readers Respond" is a forum where VFC interacts with the readers of VFC's Stock House. Readers can leave comments on posted material at either of the blog sites, through Seeking Alpha or via email, firstname.lastname@example.org. All stock opinions, tips and questions are welcomed, whether agreeable with VFC's opinions or not. Thanks for the comments, because without interaction - this wouldn't be fun.
A comment posted to VFC's ORIGINAL Stock House regarding the price targets of CTSO:
If the trial is successful and if this device does get the mark of approval they hope to get does your gut give you an idea of what the pps might rise to? I have heard anywhere from 1.00 to over 30.00.
appreciate your viewpoint
VFC's Take: I'll refer the reader to the last post in which I responded to the same question, CTSO Price Targets. In that posting I stated that I see fifty to seventy five cents as the immediate target for positive trial news, with the potential for much higher gains when/if CE Mark approval were to take place later this year.
Over the long run, the sky is the limit as additional filings and approvals come in, assuming Cytosorb works, because there is no other effective treatment on the market to treat severe sepsis.
You can count on the fact that dilution will become a factor after any initial price spike, limiting the short term upward mobility of the stock, in my opinion.
On the other hand, if the trial is not a success, then expect the share price to collapse, seeing as that there is no pipeline product far enough along to support a quick recovery. The company has suspended the pipeline to concentrate resources on CytoSorb, according to previous company reports.
Disclosure: Long CTSO.